DEF 14A: Arcellx, Inc. Announces 2024 Annual Meeting of Stockholders

Arcellx, Inc. will hold its annual meeting of stockholders virtually on May 24, 2024, to vote on director elections, executive compensation, and auditor ratification.

Summary

• Arcellx, Inc. is holding its annual meeting of stockholders on May 24, 2024, at 9:00 am ET, conducted virtually via live audio webcast.
• Stockholders of record as of April 1, 2024, are entitled to vote.
• The meeting will address the election of three Class II directors, an advisory vote on executive compensation (Say-on-Pay), an advisory vote on the frequency of future Say-on-Pay votes, and the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The Board recommends voting FOR the election of each director nominee, FOR the approval of the Say-on-Pay vote, for holding future Say-on-Pay votes every ONE YEAR, and FOR the ratification of the appointment of PricewaterhouseCoopers LLP.
• The notice of internet availability of proxy materials was first sent on or about April 11, 2024.
• As of the record date, there were 53,290,315 shares of common stock outstanding.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, presenting information in a neutral and factual tone. The board's recommendations are positive, but the overall sentiment is balanced and informative.

Positives

• The board is composed of a majority of independent directors, ensuring objective oversight.
• The company has established audit, compensation, and corporate governance committees to manage specific risks and responsibilities.
• The company provides a clawback policy for recoupment of compensation from officers in the event of a financial restatement or recalculation of a financial metric affecting an award.
• Stockholders have the opportunity to provide input on executive compensation through the advisory vote.

Negatives

• The document does not explicitly state any negative aspects of the company's performance or governance.
• The company changed independent registered public accounting firms from Ernst & Young LLP to PricewaterhouseCoopers LLP for the fiscal year ending December 31, 2024.

Risks

• The advisory vote on executive compensation is non-binding, so the board is not obligated to act on the outcome.
• The limitation of liability and indemnification provisions in the company's charter and bylaws may discourage stockholders from bringing lawsuits against directors.
• The company's success depends on attracting and retaining qualified personnel as directors and officers.

Future Outlook

The document outlines the procedures for stockholders to submit proposals or director nominations for the 2025 annual meeting, indicating a focus on future corporate governance.

Management Comments

• Rami Elghandour, President, Chief Executive Officer and Chairman, expressed appreciation for stockholders' continued support and interest in Arcellx.
• The board believes that Mr. Elghandours service as both Chairman of the Board and Chief Executive Officer is in the best interest of the Company and its stockholders.

Industry Context

As a biotech company, Arcellx's corporate governance and executive compensation practices are likely being scrutinized by investors and industry analysts, especially in light of the company's reliance on equity-based compensation.

Comparison to Industry Standards

• The director compensation policy is developed with input from an independent compensation consultant regarding practices and compensation levels at comparable companies.
• The document does not provide specific details on comparable companies or benchmarks used to determine executive compensation.
• The company's approach to risk oversight, with board committees responsible for specific areas, is a common practice among publicly traded companies.

Related Party Transactions

• Entities affiliated with SR One Capital Fund I Aggregator, L.P. (affiliated with director Jill Carroll) purchased 1,666,667 shares of common stock in the IPO at $15 per share.
• Entities affiliated with New Enterprise Associates 15, L.P. (affiliated with directors Ali Behbahani and Kavita Patel) purchased 1,583,333 shares of common stock in the IPO at $15 per share.
• Entities affiliated with New Enterprise Associates 15, L.P. (affiliated with directors Ali Behbahani and Kavita Patel) purchased 312,500 shares of common stock in the secondary public offering at a price of $16.00 per share.
• Gilead Sciences, Inc. (Gilead) purchased 3,478,261 shares for approximately $100 million on January 30, 2023.
• Gilead Sciences, Inc. (Gilead) purchased 3,242,542 shares for approximately $200 million on December 28, 2023.
• Arcellx is party to a Collaboration and License Agreement entered into on December 9, 2022 between Arcellx and Kite and as amended in November 2023, pursuant to which Arcellx received upfront cash payments of $225 million in February 2023 and $85 million in November 2023.
• Arcellx is party to an Amended and Restated Standstill and Stock Restriction Agreement entered into on November 15, 2023 between Arcellx and Gilead, which amended and restated in its entirety the Standstill and Stock Restriction Agreement entered into on December 8, 2022 between Arcellx and Gilead, pursuant to which Gilead agreed to certain transfer and standstill restrictions.

Stakeholder Impact

• Stockholders have the opportunity to vote on key corporate governance matters, including director elections and executive compensation.
• The outcome of the Say-on-Pay vote may influence future executive compensation decisions.
• The ratification of the independent auditor ensures the integrity of the company's financial reporting.

Next Steps

• Stockholders are urged to vote on the proposals outlined in the proxy statement.
• The company will disclose voting results on a Current Report on Form 8-K within four business days after the meeting.
• The board of directors and compensation committee will consider the outcome of the advisory votes when making future decisions regarding executive compensation and the frequency of Say-on-Pay votes.

Key Dates

Keywords

annual meeting, proxy statement, directors, executive compensation, audit committee, stockholders, corporate governance, PricewaterhouseCoopers, Arcellx